Activation
and reduction of O2 and H2O2 by synthetic
and biosynthetic iron porphyrin models have
proved to be a versatile platform for evaluating second-sphere effects
deemed important in naturally occurring heme active sites. Advances
in synthetic techniques have made it possible to install different
functional groups around the porphyrin ligand, recreating artificial
analogues of the proximal and distal sites encountered in the heme
proteins. Using judicious choices of these substituents, several of
the elegant second-sphere effects that are proposed to be important
in the reactivity of key heme proteins have been evaluated under controlled
environments, adding fundamental insight into the roles played by
these weak interactions in nature. This review presents a detailed
description of these efforts and how these have not only demystified
these second-sphere effects but also how the knowledge obtained resulted
in functional mimics of these heme enzymes.
Oxygen reduction reaction (ORR) is
a complex 4e–/4H+ multistep process,
and factors that determine the
rate and selectivity of this reaction are a matter of contemporary
interest. Synthetic iron porphyrin model complexes mimicking the active
site of horseradish peroxidase (HRP) are shown to enhance the rate
of ORR and 4H+/4e– selectivity irrespective
of the rate of electron transfer from the electrode relative to unfunctionalized
iron porphyrins. In operando spectroscopic analysis over self-assembled
monolayer-modified electrodes allows characterization of reactive
intermediates involved in ORR. Two key intermediate species of ORR,
FeIII–OOH and FeIVO, are identified
using 18O2 labeling depending on the nature
of the pendant residue of these HRP mimics. The results indicate that
the nature of the pendant distal moiety in the distal superstructure
of iron porphyrin changes the distribution of the intermediate species
under steady state relative to simple mononuclear porphyrins. Density
functional theory calculations indicate that not only the presence
of hydrogen bonding from the pendant groups but also its relative
spatial orientation with respect to the proximal and distal oxygen
atom of a FeIII–OOH intermediate species controls
the selectivity of ORR.
The mononuclear copper hydroperoxo species (Cu(ii)–OOH) of Cu–Aβ is the active oxidant responsible for serotonin oxidation by Cu–Aβ in the presence of physiologically relevant oxidants like O2 and H2O2, which can potentially cause oxidative degradation of neurotransmitters, a marker of Alzheimer's disease.
Understanding the reactivity landscape for the activation of water till the formation of the O-O bond and O 2 release in molecular chemistry is a decisive step in guiding the elaboration of costeffective catalysts for the oxygen-evolving reaction (OER). Copper (II) complexes have recently caught the attention of chemists as catalysts for the 4e -/4H + water oxidation process. While a copper (IV) intermediate has been proposed as the reactive intermediate species, yet no spectroscopic signature has been reported so far. Copper (III) ligand radical species have also been formulated and supported by theoretical studies. We found, herein, that the reactivity sequence for the water oxidation with a family of Copper (II) o-phenylene bisoxamidate complexes are a function of the substitution pattern on the periphery of the aromatic ring. In-situ IR, EPR and rR spectroelectrochemical studies helped to sequence the elementary electrochemical and chemical events leading towards the O 2 formation selectively at the copper center. A copper (II) superoxide species is identified as the reactive intermediate, the stability of which governs the selectivity of 4eoxidation of water to molecular oxygen.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.